Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• B-cell chronic lymphocytic leukaemia (B-CLL) is an incurable malignancy of CD5(+) B cells.
• Current treatments for B-CLL lack curative options.

Purpose of the Study:

• To investigate a novel immunotherapy approach for B-cell malignancies.
• To redirect cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTL) to target B-CLL cells.

Main Methods:

• Utilized a streptavidin-fused anti-CD20 single-chain variable fragment (scFv) combined with biotinylated MHC class I molecules containing CMV pp65 peptide (HLA/CMV).
• Assessed the lysis of B-CLL cells coated with the CD20-HLA/CMV complex by autologous CMV-specific CTL.
• Measured T-cell proliferation and cytokine production (interferon gamma, tumor necrosis factor alpha, macrophage inflammatory protein-1 beta) in response to complex-coated B-CLL cells.

Main Results:

• B-CLL cells coated with the CD20-HLA/CMV complex were efficiently lysed by autologous CMV-specific CTL.
• Killing was HLA-restricted and dependent on scFv CD20 and HLA/CMV concentrations.
• Complex-coated B-CLL cells induced proliferation and cytokine release in CMV-specific CD8(+) T cells.

Conclusions:

• The novel CD20-HLA/CMV complex effectively redirects CTL to target B-CLL.
• This approach shows promise for the immunotherapy of B-cell malignancies.
• Further steps are established for potential clinical application.